Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
Trial details
- Registry ID
- NCT05973006
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as NVX-CoV2601
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3 Adolescent Study for SARS-CoV-2 rS Variant VaccinesNCT05973006 | Novavax | Phase 3 | Completed | 2024-04-01Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |